Compare Fastenal Company Common Stock (FAST) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fastenal Company Common Stock vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Fastenal Company Common Stock trades at $52.13 (market cap $59.02B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Fastenal Company Common Stock is far larger — about 60.7× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Fastenal Company Common Stock pays a 1.87% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fastenal Company Common Stock for 2 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| FAST | MRVI | |
|---|---|---|
Market Cap | $59.02B | $972.90M |
Volume | 10,054,911 | 4,325,710 |
Sector | Industrials | Health |
52-Week High | $52.38 | $9.00 |
52-Week Low | $39.15 | $2.83 |
Typical Hold Time | 2 Days | 0 Days |
Enterprise Value | $59.25B | $1.08B |
Dividend Yield | 1.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fastenal (FAST) trades at $51.43, down 0.12% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with Q3 2026 earnings of $0.35 per share beating estimates, marking the fourth consecutive quarterly beat. Revenue grew 15.5% year-over-year to $2.46 billion, driven by market share gains and new contract wins. The stock shows resilience with consistent operational performance despite premium valuation metrics.
Outlook remains positive with strong industrial demand and digital initiatives supporting growth, though the elevated P/E ratio of 43.96 presents valuation risk. Analyst consensus leans cautious with 59% hold ratings, suggesting limited near-term upside from current levels. Key risks include economic sensitivity and competitive pressures in industrial distribution.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fastenal Company Common Stock
Fastenal distributes fasteners, tools, safety supplies, and other industrial products. It also provides inventory management and vending solutions for business customers.
Read more on FAST →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
